Skip to Content

RespireRx Pharmaceuticals Inc RSPI

Morningstar Rating
$0.00 0.00 (5.88%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

RSPI is trading at a 817% premium.
Price
$0.00
Fair Value
$9.54
Uncertainty
Extreme
1-Star Price
$1.15
5-Star Price
$8.84
Economic Moat
Mpt
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RSPI is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.00
Day Range
$0.000.00
52-Week Range
$0.000.02
Bid/Ask
$0.00 / $0.00
Market Cap
$424,567.14
Volume/Avg
1.6 Mil / 7.3 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

RespireRx Pharmaceuticals Inc is engaged in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The pipeline products of the company are dronabinol which is developed for the treatment of OSA (Obstructive Sleep Apnea), a form of sleep apnea; CX1739 for the treatment of chronic central sleep apnea; CX717 and CX1942 is an injectable dosage for respiratory depression or vaso-occlusive passes associated with sickle cell disease. The company also focuses on developing another class of compounds called ampakines for the treatment of various respiratory disorders.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
2

Valuation

Metric
RSPI
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
RSPI

Financial Strength

Metric
RSPI
Quick Ratio
0.00
Current Ratio
0.01
Interest Coverage
−3.12
Quick Ratio
RSPI

Profitability

Metric
RSPI
Return on Assets (Normalized)
−2,286.13%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
RSPI
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRSdxpznpmJvph$586.3 Bil
VRTX
Vertex Pharmaceuticals IncHdrwddqnVfmytbg$115.1 Bil
REGN
Regeneron Pharmaceuticals IncVmqqgyjwhFfgskl$108.2 Bil
MRNA
Moderna IncRynyxytbFjlkh$54.0 Bil
ARGX
argenx SE ADRCwgfwmztDgkgy$22.0 Bil
BNTX
BioNTech SE ADRLzqmjhzrDlzhm$21.8 Bil
ALNY
Alnylam Pharmaceuticals IncBnqfvmyHfjxpl$18.9 Bil
BMRN
Biomarin Pharmaceutical IncVdrlvdbmCzfzp$14.6 Bil
INCY
Incyte CorpYjdzctcgDzmdpw$12.9 Bil
RPRX
Royalty Pharma PLC Class AZynskdxkqjTbmdr$12.3 Bil

Sponsor Center